At the news
? NEUTRALIMPACT 2/10 8-K filed May 20, 2026 at 16:10 ET
Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders approved amendments to the 2018 Equity Incentive Plan and 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares respectively, and ratified Ernst & Young as auditor. No director departures or officer changes occurred.
- Shareholders approved amendment to 2018 Equity Incentive Plan, adding 500,000 shares
- Shareholders approved amendment to 2000 Employee Stock Purchase Plan, adding 360,000 shares
- All three director nominees (Hannah, Moos, Rodriguez) were elected
- Say-on-pay and ratification of Ernst & Young as auditor passed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access